


Supplementary Figure S1. ADCC reporter bioassay by EpMab-37 in the presence Capan-2 cells. Target cells (Capan-2) were treated with serially diluted EpMab-37. Then, Jurkat cells stably expressing the human FcγRIIIa receptor, and an NFAT response element driving firefly luciferase were added and co-cultured. Luminescence was measured using the Bio-Glo Luciferase Assay System. ADCC, antibody-dependent cellular cytotoxicity.



Supplementary Figure S2. ADCC reporter bioassay by EpMab-37-mG_{2a}-f and trastuzumab in the presence BT-474 cells. Target cells (BT-474 cells) were treated with serially diluted EpMab-37-mG_{2a}-f (left) and trastuzumab (right). Then, Jurkat cells stably expressing the human FcγRIIIa receptor, and an NFAT response element driving firefly luciferase were added and co-cultured. Luminescence was measured using the Bio-Glo Luciferase Assay System. ADCC, antibody-dependent cellular cytotoxicity.